Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT)

: HFPEF patients in the Swedish Heart Failure Registry (2550 patients) and HFPEF patients in US (650 patients). HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N

n-terminal pro-bnp
aldosterone
natriuretic peptide
spironolactone
aldosterone antagonists
  • 69 views
  • 01 Mar, 2022
  • 65 locations
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction (ASTRAAS-HF)

to evaluate the effect of IONIS-AGT-LRx weekly SC injection on plasma AGT concentration and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) levels at each scheduled visit in chronic

  • 0 views
  • 23 Apr, 2022
  • 22 locations
An Open-Label Study of Apabetalone in Covid Infection

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

  • 4 views
  • 22 Mar, 2022
  • 1 location
Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

The purpose of this study is to: 1) Remodel and restore left ventricular geometry and function. 2) Avoid the need for mechanical circulatory support (MCS) and/or cardiac transplantation (CT). 3) Confirm the outcomes of a pilot study completed in Germany and reported in The Journal of Heart and Lung Transplantation …

  • 5 views
  • 10 Apr, 2022
  • 1 location
Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)

Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and eventually to death. The therapeutic strategy has become complex and needs to perform recurring follow up evaluations including right heart catheterizations (RHC). Cardiac magnetic resonance imaging (cMRI) has the advantage …

  • 0 views
  • 10 May, 2021
  • 1 location
Tailoring Pacemaker Output to Physiology in Chronic Heart Failure

Aims: To explore the clinical effect on exercise tolerance and quality of life, safety and tolerability of pacing at higher outputs in patients with chronic heart failure and a pacemaker. Background: Heart failure (HF) is a very common condition of breathlessness or fatigue associated with heart muscle weakness. In around …

left ventricular systolic dysfunction
cardiopulmonary exercise testing
exercise test
dyspnea
cardiac resynchronization therapy
  • 0 views
  • 02 Mar, 2022
  • 1 location
Asian Diabetes Outcomes Prevention Trial (ADOPT)

The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (>125pg/mL), and (2) intensify therapy

heart failure
diabetes
stroke
primary prevention
stenosis
  • 148 views
  • 27 Feb, 2022
  • 1 location
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

outcome is recurrent stroke and the key secondary outcome is occurrence of major cardiovascular events by trial end. Additional biomarker outcomes are change in hs-CRP insulin resistance, B type

glycosylated hemoglobin
diabetes
diabetes mellitus
glomerular filtration rate
pioglitazone
  • 0 views
  • 24 Mar, 2022
  • 1 location
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

This is a double-blind, placebo-controlled and open-label, multicenter efficacy and long-term safety study of firibastat (QGC001) 1000 mg (2500 mg tablets) administered po, QD, for up to 48 weeks in patients with difficult-to-treat/treatment-resistant HTN. Subjects will continue to take their chronic antihypertensive therapies (at least 2 classes of antihypertensive therapies) …

blood pressure diastolic
resistant hypertension
antihypertensive drugs
hypertension
  • 0 views
  • 28 Sep, 2021
  • 2 locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

anthracyclines
blast cells
daunorubicin
cell transplantation
cytarabine/daunorubicin
  • 141 views
  • 10 May, 2022
  • 98 locations